Literature DB >> 29526507

Stereochemical and structural effects of (2R,6R)-hydroxynorketamine on the mitochondrial metabolome in PC-12 cells.

Andréa T Faccio1, Francisco J Ruperez2, Nagendra S Singh3, Santiago Angulo2, Marina F M Tavares4, Michel Bernier5, Coral Barbas2, Irving W Wainer6.   

Abstract

BACKGROUND: Impairment in mitochondrial biogenesis and function plays a key role in depression and anxiety, both of which being associated with changes in fatty acid and phospholipid metabolism. The antidepressant effects of (R,S)-ketamine have been linked to its conversion into (2S,6S;2R,6R)-hydroxynorketamine (HNK); however, the connection between structure and stereochemistry of ketamine and HNK in the mitochondrial homeostatic response has not yet been fully elucidated at a metabolic level.
METHODS: We used a multi-platform, non-targeted metabolomics approach to study the change in mitochondrial metabolome of PC-12 cells treated with ketamine and HNK enantiomers. The identified metabolites were grouped into pathways in order to assess global responses.
RESULTS: Treatment with (2R,6R)-HNK elicited the significant change in 49 metabolites and associated pathways implicated in fundamental mitochondrial functions such as TCA cycle, branched-chain amino acid biosynthetic pathway, glycoxylate metabolic pathway, and fatty acid β-oxidation. The affected metabolites included glycerate, citrate, leucine, N,N-dimethylglycine, 3-hexenedioic acid, and carnitine and attenuated signals associated with 9 fatty acids and elaidic acid. Important metabolites involved in the purine and pyrimidine pathways were also affected by (2R-6R)-HNK. This global metabolic profile was not as strongly impacted by treatment with (2S,6S)-HNK, (R)- and (S)-ketamine and in some instances opposite effects were observed.
CONCLUSIONS: The present data provide an overall view of the metabolic changes in mitochondrial function produced by (2R,6R)-HNK and related ketamine compounds and offer an insight into the source of the observed variance in antidepressant response elicited by the compounds.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidepressants; Hydroxynorketamine; Ketamine; Metabolomics; Mitochondria; Stereochemistry

Mesh:

Substances:

Year:  2018        PMID: 29526507      PMCID: PMC6053273          DOI: 10.1016/j.bbagen.2018.03.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  78 in total

1.  mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation.

Authors:  Masahiro Morita; Simon-Pierre Gravel; Valérie Chénard; Kristina Sikström; Liang Zheng; Tommy Alain; Valentina Gandin; Daina Avizonis; Meztli Arguello; Chadi Zakaria; Shannon McLaughlan; Yann Nouet; Arnim Pause; Michael Pollak; Eyal Gottlieb; Ola Larsson; Julie St-Pierre; Ivan Topisirovic; Nahum Sonenberg
Journal:  Cell Metab       Date:  2013-11-05       Impact factor: 27.287

2.  Fishing in the (deoxyribonucleotide) pool.

Authors:  Ann Saada
Journal:  Biochem J       Date:  2009-08-27       Impact factor: 3.857

3.  The economic burden of adults with major depressive disorder in the United States (2005 and 2010).

Authors:  Paul E Greenberg; Andree-Anne Fournier; Tammy Sisitsky; Crystal T Pike; Ronald C Kessler
Journal:  J Clin Psychiatry       Date:  2015-02       Impact factor: 4.384

4.  Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.

Authors:  E Beurel; L Song; R S Jope
Journal:  Mol Psychiatry       Date:  2011-04-19       Impact factor: 15.992

Review 5.  Untargeted Metabolomics Strategies-Challenges and Emerging Directions.

Authors:  Alexandra C Schrimpe-Rutledge; Simona G Codreanu; Stacy D Sherrod; John A McLean
Journal:  J Am Soc Mass Spectrom       Date:  2016-09-13       Impact factor: 3.109

6.  A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin.

Authors:  Gareth J Browne; Christopher G Proud
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

7.  Modulation of the voltage-dependent anion channel of mitochondria by elaidic acid.

Authors:  Debanjan Tewari; Amal Kanti Bera
Journal:  Biochem Biophys Res Commun       Date:  2016-06-16       Impact factor: 3.575

8.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

9.  Regulation of GluA1 AMPA receptor through PKC phosphorylation induced by free fatty acid derivative HUHS2002.

Authors:  Takaaki Nishimoto; Takeshi Kanno; Tadashi Shimizu; Akito Tanaka; Tomoyuki Nishizaki
Journal:  Lipids       Date:  2012-11-02       Impact factor: 1.880

Review 10.  Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties.

Authors:  P A Zunszain; M A Horowitz; A Cattaneo; M M Lupi; C M Pariante
Journal:  Mol Psychiatry       Date:  2013-07-23       Impact factor: 15.992

View more
  5 in total

Review 1.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

2.  Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.

Authors:  Jaclyn N Highland; Patrick J Morris; Panos Zanos; Jacqueline Lovett; Soumita Ghosh; Amy Q Wang; Carlos A Zarate; Craig J Thomas; Ruin Moaddel; Todd D Gould
Journal:  J Psychopharmacol       Date:  2018-11-29       Impact factor: 4.153

Review 3.  Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity.

Authors:  Eric S Schwenk; Basant Pradhan; Rohit Nalamasu; Lucas Stolle; Irving W Wainer; Michael Cirullo; Alexander Olsen; Joseph V Pergolizzi; Marc C Torjman; Eugene R Viscusi
Journal:  Curr Pain Headache Rep       Date:  2021-07-16

4.  Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.

Authors:  Cristan A Farmer; Jessica R Gilbert; Ruin Moaddel; Jomy George; Lilian Adeojo; Jacqueline Lovett; Allison C Nugent; Bashkim Kadriu; Peixiong Yuan; Todd D Gould; Lawrence T Park; Carlos A Zarate
Journal:  Neuropsychopharmacology       Date:  2020-04-06       Impact factor: 7.853

5.  Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.

Authors:  Panos Zanos; Cristan A Farmer; Ruin Moaddel; Bashkim Kadriu; Patrick J Morris; Jacqueline Lovett; Elia E Acevedo-Diaz; Grace W Cavanaugh; Peixiong Yuan; Mani Yavi; Craig J Thomas; Lawrence T Park; Luigi Ferrucci; Todd D Gould; Carlos A Zarate
Journal:  Transl Psychiatry       Date:  2022-05-02       Impact factor: 7.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.